Denali Therapeutics earnings date
Want to see DNLI full AI Analyst Report?
Denali Therapeutics (DNLI) Q3 2026 Earnings Report
DNLI Q3 2026 EPS Results
- Actual EPS
- $0.37
- Consensus EPS
- -$0.27
- Beat/Miss
- Beat by +$0.64
- One Year Ago EPS
- -$0.74
DNLI Q3 2026 Revenue Results
- Actual Revenue
- $17.78M
- Expected Revenue
- $12.67M
- Beat/Miss
- Beat by +$5.11M
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/03/2026
- Time
- After Close
- Conference Call
- Tuesday, November 3, 2026
Denali Therapeutics's next earnings date is estimated for March 1, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive, led by AVLAYAH revenue of $17.8 million, revenue guidance of $30 million to $32 million for the fourth quarter, rapid expansion of payer coverage, completed COMPASS enrollment, and multiple clinical milestones expected in 2027. Management also highlighted a $1.01 billion cash balance and flat operating expenses year over year. The main cautions were that the initial revenue step-up is not a steady-state run rate, annual guidance has not been established, patient access timelines remain variable, the Sanfilippo filing depends on manufacturing readiness, and several pipeline programs still require future clinical and biomarker validation.
Denali expects AVLAYAH fourth-quarter net product revenue of $30 million to $32 million, which would be more than 65% growth over this quarter; the company expects revenue to keep growing at a steadier pace over the next several quarters, has not decided whether or not it will guide annually, expects COMPASS to complete around the end of 2027 and data in the first half of 2028, expects the zafinofusp alfa data package could support a BLA submission in 2027 and plans to present the full data set at a medical congress in the first quarter of 2027, expects initial clinical biomarker data for DNL628 in the first half of 2027 and initial safety and clinical proof-of-concept data for DNL921 in 2027, and through 2028 aims to build 2 growing commercial brands, establish 5 clinical proof of concept and bring 4 to 6 additional programs into the clinic.
- AVLAYAH Revenue Significantly Exceeded GuidanceAVLAYAH generated $17.8 million in net product revenue in the second full commercial quarter, up almost fivefold from $3.6 million in the first full quarter and above the guided range of $10 million to $12 million. Fourth-quarter revenue guidance is $30 million to $32 million, representing more than 65% growth over the third quarter.
- Rapid Expansion of Payer AccessCommercial coverage increased from 50% to more than 70% of covered lives during the quarter. Twenty state Medicaid programs now list AVLAYAH as covered, up from 14 last quarter, and a permanent J-code became effective October 1 to simplify billing and reimbursement.
- Strong Launch Engagement and Patient Access ProgressDenali reached approximately 90% of its targeted health care organizations since launch. The company said patient interest, physician engagement and access are moving faster than expected, and that the majority of eligible Phase I/II patients moved to commercial treatment sooner than anticipated.
- AVLAYAH Established as a Major Hunter Syndrome MilestoneAVLAYAH is the first new FDA-approved therapy for the Hunter syndrome community in nearly 20 years, the first FDA-approved medicine of its kind designed to cross the blood-brain barrier through the transferrin receptor, and the first product from Denali's TransportVehicle platform.
- Large Commercial Opportunity in Hunter SyndromeDenali estimates approximately 500 people live with Hunter syndrome in the United States, including roughly 375 eligible under the current pediatric label. The company aims to reach all eligible patients and expects AVLAYAH to become the leading treatment for Hunter syndrome in the United States.
- Global Expansion Plans for AVLAYAHDenali is working with distributor partners in Latin America, the GCC and select Asia Pacific markets while determining the appropriate regulatory paths. COMPASS is expected to support broader approvals and European reimbursement, with a long-term goal of reaching approximately 2,000 people with MPS II in commercially accessible geographies.
- COMPASS Enrollment CompletedThe global randomized, double-blind, active-controlled Phase II/III COMPASS study completed enrollment in Cohort B, bringing total enrollment across Cohorts A and B to 65 participants. The study is designed to support conversion to full U.S. approval, potential expansion of the label to adults, and global regulatory and reimbursement decisions.
- Sanfilippo Program Reached a Key Development MilestoneThe Phase I/II study of zafinofusp alfa in Sanfilippo syndrome type A completed the prespecified treatment duration for the primary endpoint. Denali expects the resulting data package could support a BLA submission in 2027, seeking accelerated approval, and plans to present the full data set at a medical congress in the first quarter of 2027.
- Encouraging Preliminary Zafinofusp Alfa Biomarker ResultsAt week 49, mean CSF heparan sulfate was reduced by 80%, with 3 of 7 assessed participants reaching the normal range. The study also showed a 61% mean reduction in CSF GM3, an 83% mean reduction in urine heparan sulfate, and normalization of liver volume in all assessed participants.
- Alzheimer's Programs Advanced Into Clinical TestingBoth Alzheimer's programs are now in the clinic. DNL628 is being studied in a randomized, placebo-controlled Phase Ib trial in people with biomarker-confirmed early Alzheimer's disease, with initial clinical biomarker data expected in the first half of 2027. DNL921 is in an ongoing Phase I/Ib study, with initial safety and clinical proof-of-concept data expected in 2027.
- Broad 2027 TransportVehicle Data ReadoutsDenali expects data from five TransportVehicle programs in 2027: zafinofusp alfa in the first quarter; DNL593 in FTD granulin; DNL628 in Alzheimer's in the first half; and initial data from DNL921 in Alzheimer's and DNL952 in Pompe disease.
- Broad Pipeline and Market OpportunityDenali's pipeline includes Hunter syndrome, Sanfilippo syndrome type A, FTD granulin, Pompe disease, Alzheimer's disease and Parkinson's disease. The company estimates that its rare genetic disease indications affect more than 30,000 people worldwide and that Alzheimer's and Parkinson's affect more than 40 million people.
- Two-Franchise Portfolio StrategyDenali is pursuing brain-penetrant enzyme replacement therapies, with AVLAYAH as the commercial foundation, alongside TransportVehicle-enabled programs for common neurodegenerative diseases. The company estimates the conventional enzyme replacement therapy market at more than $9 billion and stated that each common neurodegenerative indication has commercial potential of more than $5 billion.
- Strong Financial Position and Capital EfficiencyThird-quarter operating expenses and year-to-date operating expenses were essentially flat compared with the same periods last year despite the commercial build for AVLAYAH and pipeline progress. Third-quarter net income was $70.1 million, primarily due to one-time gross proceeds of $195 million from the sale of the priority review voucher, and Denali ended September with approximately $1.01 billion in cash, cash equivalents and marketable securities.
- Clear Three-Year Strategic GoalsDenali introduced its D3x3 goals through 2028: build two growing commercial brands, establish five clinical proof-of-concept programs, and bring four to six additional programs into the clinic.
- Commercial Infrastructure Supports Future Zafinofusp Alfa LaunchDenali stated that the commercial infrastructure built for AVLAYAH is expected to support the launch of zafinofusp alfa because the products have a similar customer base. The company expects the existing community engagement, stakeholder trust and launch capabilities to help expedite the second product's launch.
- Chronic Therapy and Pricing DetailsThe current AVLAYAH price is $5,200 per vial, and Denali stated that the cost for an average 30-kilogram patient would be about $811,000. The company described AVLAYAH as a chronic weekly therapy and said there is a very high level of patients remaining on drug, while noting that it is still too early to determine actual persistence.
DNLI Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 01, 2027 | 2026 (Q4) | -0.61- | -0.73 | ― | ― |
| Nov 03, 2026 | 2026 (Q3) | -0.270.37 | -0.74 | 150.00% (+1.11) | |
| Aug 06, 2026 | 2026 (Q2) | -0.51-0.68 | -0.72 | 5.56% (+0.04) | |
| May 07, 2026 | 2026 (Q1) | -0.72-0.69 | -0.78 | 11.54% (+0.09) | |
| Feb 26, 2026 | 2025 (Q4) | -0.74-0.73 | -0.67 | -8.96% (-0.06) | |
| Nov 06, 2025 | 2025 (Q3) | -0.75-0.74 | -0.63 | -17.46% (-0.11) | |
| Aug 11, 2025 | 2025 (Q2) | -0.71-0.72 | -0.59 | -22.03% (-0.13) | |
| May 06, 2025 | 2025 (Q1) | -0.70-0.78 | -0.68 | -14.71% (-0.10) | |
| Feb 27, 2025 | 2024 (Q4) | -0.80-0.67 | -0.86 | 22.09% (+0.19) | |
| Nov 06, 2024 | 2024 (Q3) | -0.59-0.63 | -0.72 | 12.50% (+0.09) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

